Kyowa Hakko Kogyo Co., Ltd.

Other

Kyowa Hakko Kogyo Kabushiki Kaisha

Tatsuya Tamaoki

Chikara Murakata

Yukimasa Shiotsu

Toshikazu Kamiya

Shiro Akinaga

Yoshiharu Yokoo

Fusao Tomita

Tomoya Takahashi

Isami Takahashi

Yutaka Saitoh

Makoto Morimoto

Masaji Kasai

Kunikatsu Shirahata

Masami Okabe

Shun-ichi Ikeda

Takako Shiraki

Hiroyuki Yamaguchi

Motoo Yamasaki

Yutaka Kanda

Katsuhiko Ando

Tadashi Ashizawa

Takao Iida

Hitoshi Arai

Fumihiko Kanai

Mayumi Yoshida

Kinya Yamashita

Akio Shirai

Junichi Watanabe

Takeshi Takahashi

Hiroshi Sano

Kenji Shibata

Masato Satomura

Yutaka Saito

Hiroshi Kawamoto

Tadashi Inaba

Hirofumi Nakano

Masanobu Takashima

Fumio Suzuki

Hiroshi Takeuchi

Yoshihisa Tsukada

Hiroshi Kitaguchi

Hiromitsu Saito

Isao Kawamoto

Kazuhisa Uchida

Hideharu Anazawa

Keiko Ochiai

Tamio Mizukami

Kenji Ohmori

Yoshiyuki Yonetani

Naoki Asanuma

Tetsuo Oka

Takeshi Kuroda

Shinkichi Honda

Soichiro Sato

Haruhiko Yokoi

Nobuo Kosaka

Kozo Asano

Noriaki Hirayama

Yoko Kato

Yoshinori Kobayashi

Hiroyuki Nagata

Kazuhisa Fujimoto

Hiroshi Nakajima

Takashi Kawakita

Yoichiro Arai

Nobuo Nakamura

Shuji Okubo

Noboru Konishi

Hiromasa Kato

Toshiaki Iwazaki

Yumiko Aotani

Hisayo Nomoto

Kenji Torii

Takako Iida

Yoji Ikuina

Masako Hamada

Masanori Fukui

Yuko Kanda

Michio Kawamura

Teruo Kishi

Disclosed is a safe and effective hair-growing agent comprising a protein kinase C-specific inhibitor.

Hair-growing agent

The present invention relates to a fusion polypeptide which comprises a polypeptide having G-CSF activity and a polypeptide having TPO activity and DNA which codes for the fusion polypeptide, to a fusion polypeptide in which a polypeptide having G-CSF activity and a polypeptide having TPO activity are fused via a spacer peptide and DNA which codes for the fusion polypeptide and to a polypeptide in which the fusion polypeptide comprising a polypeptide having G-CSF activity and a polypeptide having TPO activity is chemically modified with a polyalkylene glycol derivative. It also relates to an anemia-treating composition containing the fusion polypeptide as an active ingredient.

hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same

Bisaryl compound and medicament for cancer treatment comprising the same

Hair-growing agent comprised of proanthocyanidins

DC107 derivatives represented by formula (I) or pharmaceutically acceptable salts thereof which have antimicrobial activity and antitumor activity are provided: ##STR1## wherein R.sup.1 represents CO(CR.sup.4A R.sup.4B).sub.n1 (O(CH.sub.2).sub.p1).sub.n2 OR.sup.5 {wherein n1 represents an integer of 1 or 2; R.sup.4A and R.sup.4B are the same or different, and each represents hydrogen or lower alkyl; p1 and n2 each represents an integer of 1 to 10; and R.sup.5 represents hydrogen, lower alkyl, or the like), or ##STR2##

DC107 derivatives

DC107 derivatives represented by formula (I) or pharmaceutically acceptable salts thereof which have antimicrobial activity and antitumor activity are provided: ##STR1## wherein R.sup.1 represents hydrogen, lower alkoxyalkyl, aralkyloxyalkyl, lower alkoxyalkoxyalkyl, lower alkoxyalkoxyalkoxyalkyl, aralkyl, tetrahydropyranyl, COR.sup.4, or the like; R.sup.2 represents hydrogen or COR.sup.6 ; R.sup.3 represents --CH.sub.2 OCOR.sup.7, phthalimidomethyl, or the like; and W represents oxygen or NR.sup.8 (wherein R.sup.8 represents hydroxy, lower alkoxy, lower alkenyloxy, aralkyloxy, substituted or unsubstituted arylsulfonylamino, or lower alkoxycarbonylamino).

The present invention relates to compounds represented by formula (I): ##STR1## wherein Z represents Gly or Cys; X represents an (.alpha.-amino acid residue; Y represents a natural calcitonin moiety, a partial natural calcitonin peptide moiety, or a natural calcitonin-like peptide moiety; m represents an integer of 5-8, .alpha.-amino acid residues represented by X being the same or different; and n represents an integer of 0-3; provided that when m is 5, the sequence of 4 C-terminal residues of --(X).sub.m -- is different from the sequence of the third to sixth amino acids of natural calcitonin, and pharmaceutically acceptable salts thereof.

Calcitonin derivatives

The present invention relates to compound LK6-A represented by the formula: ##STR1## which has immunosuppressive activity, and pharmaceutically acceptable salts thereof.

Compound LK6-A

Alkyl and aralkyl-substituted pyrrolocarbazole derivatives that

The present invention relates to therapeutic agents for thrombocytopenia which contain an indolocarbazole derivative represented by the formula (I) given below or a pharmaceutically acceptable salt thereof as an active ingredient, and to novel indolocarbazole derivatives. ##STR1##

Indolocarbazole derivatives and therapeutic method for stimulating

The present invention provides a method of treating thrombocytopenia, which comprises administering to a patient suffering from thrombocytopenia, an effective amount of an indolocarbazole derivative represented by formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group or a tetrahydropyranyl group; R.sup.2A and R.sup.3A, which may be the same or different, each represent a hydrogen atom, a substituted or unsubstituted lower alkyl group, a lower alkenyl group, a substituted or unsubstituted aralkyl group or a monosaccharide residue where a hydroxyl group at the anomer position is removed; R.sup.4A and R.sup.5A, which may be the same or different, each represent a hydrogen atom, a formyl group, a hydroxyl group or a halogen atom; W.sup.A1 and W.sup.A2 represent hydrogen atoms or are combined together to form an oxygen atom; and X.sup.A1 and X.sup.A2 represents two hydrogen atoms or are combined together to form a single bond, provided that when X.sup.A forms a single bond, then R.sup.1, R.sup.2A, R.sup.3A, R.sup.4A, R.sup.5A, and W.sup.A do not simultaneously represent a hydrogen atom, or a pharmaceutically acceptable salt.

Therapeutic agent for thrombocytopenia and indolocarbazole derivatives

Disclosed is an indolocarbazole derivative represented by the following formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## [wherein R.sup.1 represents substituted or unsubstituted lower alkyl, R.sup.2 represents hydrogen, substituted or unsubstituted lower alkyl, R.sup.3 and R.sup.4 are the same or different, and represent hydrogen, nitro, NR.sup.5 R.sup.6, OR.sup.9, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, or CH.dbd.NNR.sup.10 R.sup.11, W represents two hydrogen atoms or oxygen, and Me represents methyl, provided that when R.sup.1 is unsubstituted lower alkyl, R.sup.3 and R.sup.4 are not simultaneously hydrogen.

Indolocarbazole derivatives that stimulate platelet production

N-acylglutamine derivatives and cosmetic compositions

Disclosed is a pyrazolonaphthyridine compound represented by the formula: ##STR1## wherein R.sup.1 is represents hydrogen, lower alkyl, aralkyl, or substituted or unsubstituted aryl, R.sup.2 represents hydrogen, lower alkyl, thienyl, substituted or unsubsutituted aryl, hydroxy or amino, or a pharmaceutically acceptable salt thereof. The compound possesses antiinflammatory effect, immunosuppressive effect, broncho-dilatory effect and hair growth-stimulative effect.

Condensed naphthyridine derivatives

Growing community of inventors

Machida, Japan

Tatsuya Tamaoki